Eric K. Brandt
Option Care HealthAbout Eric K. Brandt
Independent director at Option Care Health since 2024; age 62. Background includes CFO of Broadcom Inc. (2007–2016), President & CEO of Avanir Pharmaceuticals (2005–2007), CFO of Allergan Inc. (1999–2005), and Vice President/Partner at The Boston Consulting Group (1989–1999). Serves on OPCH’s Compensation and Finance & Investment Committees; the Board affirms his independence under Nasdaq standards .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Broadcom Inc. | Chief Financial Officer | 2007–2016 | Led IT and finance at a Fortune 500 tech company |
| Avanir Pharmaceuticals, Inc. | President & CEO | 2005–2007 | Executive leadership; corporate strategy |
| Allergan Inc. | Roles incl. Chief Financial Officer | 1999–2005 | Finance leadership at a public pharma company |
| The Boston Consulting Group, Inc. | Vice President & Partner | 1989–1999 | Corporate strategy/business development |
External Roles
| Company | Role | Tenure | Notes |
|---|---|---|---|
| Gen Digital Inc. | Director | 2020–Present | Current U.S. public company board |
| Lam Research Corporation | Director | 2010–Present | Current U.S. public company board |
| The Macerich Company | Director | 2018–Present | Not standing for re-election at 2025 annual meeting |
| Altaba Inc. | Director | Delisted (dissolution in process) | Not counted toward OPCH overboarding limits |
| DENTSPLY Sirona Inc. | Former Director | Within last five years | Former U.S. public company board |
Board Governance
- Independence and committees: Independent; member of Compensation and Finance & Investment Committees. The Compensation Committee had 4 meetings in 2024 and the Finance & Investment Committee had 5 meetings .
- Attendance: Board met 5 times in 2024; each director attended ≥75% of Board and committee meetings during their tenure; all directors attended the 2024 annual meeting .
- Governance structure: Independent Chair; all committee members are independent; Audit Committee members meet Rule 10A-3(b)(1) criteria; executive sessions are held quarterly without management .
- Overboarding policy: No director may serve on >4 public boards; OPCH confirms Brandt’s multi-board service complies (Altaba excluded due to liquidation) .
Fixed Compensation
| Component | 2024 Amount | Basis/Notes |
|---|---|---|
| Board cash retainer | $100,000 | Annual retainer for all Non-Employee Directors |
| Compensation Committee member fee | $7,500 | Member fee for non-audit/non-finance committees |
| Finance & Investment Committee member fee | $5,000 | Member fee for Finance & Investment Committee |
| Total cash fees (reported) | $112,500 | Fees earned or paid in cash for 2024 |
- Election to receive cash retainers in RSUs: 5,325 RSUs elected in lieu of cash .
Performance Compensation
| Award Type | Grant Date | Grant Value | Award Mechanics | Vesting |
|---|---|---|---|---|
| Time-based RSUs (annual grant) | May 15, 2024 | $160,000 | Shares determined by dividing $160,000 by grant-date closing price ($30.06) with rounding for equal pro-rata vesting; granted under 2018 EIP | |
| RSU vesting schedule | — | — | RSUs vest in three equal annual installments; accelerated vesting upon change in control or termination other than for cause |
No stock options are part of the director program; 2024 program consists of cash and time-based RSUs only .
Other Directorships & Interlocks
| Potential Interlock | Relevance to OPCH | Comment |
|---|---|---|
| Lam Research (semiconductor capital equipment) | Low | Unrelated to home infusion; governance experience beneficial |
| Gen Digital (consumer cybersecurity) | Low | Unrelated to OPCH operations |
| Macerich (retail REIT) | Low | Unrelated to OPCH operations; stepping down in 2025 reduces board load |
| Altaba (dissolution) | N/A | Excluded from overboarding limits; not an active public board |
Expertise & Qualifications
- Business development and corporate strategy from CEO/CFO roles; digital/technology oversight at Broadcom; extensive public company governance experience .
Equity Ownership
| Holder | Beneficially Owned Shares | Percent of Class | RSUs Outstanding (12/31/2024) | Notes |
|---|---|---|---|---|
| Eric K. Brandt | 0 | <1% | 5,325 | Beneficial ownership table as of March 1, 2025; RSUs include annual equity and RSUs elected in lieu of cash where applicable |
- Stock ownership guidelines: Directors must retain 75% of net shares (including unvested RSUs) until owning equity equal to 3× annual cash retainer; all directors were in compliance as of 12/31/2024 .
- Hedging/pledging: Prohibited; directors may not hedge or pledge OPCH securities and must observe trading windows/pre-clearance .
Governance Assessment
- Board effectiveness: Brandt’s finance and technology background strengthens oversight on compensation and capital allocation; his service on Compensation Committee (including signing the Compensation Committee Report) indicates active engagement in pay program oversight .
- Independence and attendance: Positive signals—independent status, committee independence, and confirmed attendance at ≥75% of meetings; presence at annual meeting supports engagement .
- Compensation alignment for directors: Balanced mix—cash fees plus time-based RSUs with multi-year vesting; RSU acceleration terms disclosed; no options or special perquisites .
- Other board commitments: Potential overboarding risk mitigated by policy limits and Macerich departure in 2025; OPCH confirms compliance with guidelines .
- Shareholder sentiment context: 2024 say-on-pay approval of 50.6% reflects investor scrutiny of compensation; Compensation Committee implemented changes (longer PSU periods, reduced individual modifier weight for executives)—as a committee member, Brandt participates in oversight within a more investor-responsive framework .
RED FLAGS
- Multi-board service: Brandt serves on three other public boards; while within OPCH limits, investors often monitor overboarding—stepping down from Macerich reduces load .
- Pay program scrutiny: Low say-on-pay support in 2024 increases expectations on Compensation Committee rigor; ongoing engagement and program enhancements partly mitigate this .